FDA denies hearing to Vanda on jet lag indication for sleep disorder drug

2024-03-05

The FDA on Tuesday turned down Vanda Pharmaceuticals’ request for a hearing on issues the agency found with the company’s application for a jet lag indication for its sleep disorder drug Hetlioz, another blow to the company and its strained relationship with the agency. The FDA’s decision nixes chances that Vanda’s Hetlioz, which is approved for other sleep disorders, will be granted an indication for jet lag disorder. The FDA cited issues with the endpoints used in the trials, said there was no debate about the facts and data for the drug, and that it wasn’t in the public interest to reconsider.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构